HealthExpress: Pharmaceuticals and More UK

Parkinson’s DBS: How Deep Brain Stimulation Works and Who Is a Good Candidate

Parkinson’s DBS: How Deep Brain Stimulation Works and Who Is a Good Candidate
By Vincent Kingsworth 26 Feb 2026

For many people with Parkinson’s disease, medication like levodopa works well at first. But over time, the effects wear off faster, unwanted movements (dyskinesias) start popping up, and days become a cycle of ON and OFF periods. That’s where deep brain stimulation (DBS) comes in - not as a cure, but as a powerful tool to regain control when drugs alone aren’t enough.

What Exactly Is Deep Brain Stimulation?

DBS is a surgical treatment that uses mild electrical pulses to calm overactive brain circuits causing Parkinson’s symptoms. It’s not a new idea - the first successful use for Parkinson’s happened in the late 1990s - but today’s systems are far more advanced. Tiny electrodes, thinner than a pencil lead, are placed deep inside the brain. These connect to a small battery-powered device, usually implanted under the skin near the collarbone or abdomen. The device sends continuous, adjustable pulses to specific brain targets, blocking the faulty signals that cause tremors, stiffness, and slowness.

Modern devices like Medtronic’s Percept™ PC and Boston Scientific’s Vercise™ Genus™ don’t just zap the brain - they listen too. They record brain activity in real time, especially the abnormal beta wave patterns (13-35 Hz) linked to Parkinson’s motor symptoms. Some even adjust stimulation automatically based on what the brain is doing. This is called closed-loop DBS, and early data from the INTREPID trial shows it gives 27% better symptom control than older systems that just pump out constant pulses.

Which Parts of the Brain Are Targeted?

Not all brain targets are the same. The two most common are the subthalamic nucleus (STN) and the globus pallidus interna (GPi). Choosing between them isn’t just about which one works better - it’s about what matters most to the patient.

  • STN tends to let people cut their levodopa dose by 30-50%. That means fewer drug side effects like nausea, hallucinations, or sudden drowsiness. But it can sometimes make thinking, speech, or mood worse - especially in people already at risk for cognitive changes.
  • GPi is better at reducing dyskinesias (up to 70% improvement) without needing to lower medication as much. It’s also less likely to affect thinking or mood. For someone with severe involuntary movements or a history of depression, GPi might be the safer pick.

The VA/NINDS CSP #468 trial found both targets improved movement by about the same amount - roughly half. But GPi had clearer advantages for dyskinesia and cognitive safety. That’s why many experts now recommend GPi for older patients or those with existing memory or mood issues.

Who Is a Good Candidate for DBS?

DBS isn’t for everyone. Even if you have Parkinson’s, you might not qualify. The criteria are strict - and they’re based on decades of research, not guesswork.

First, you need to have idiopathic Parkinson’s - not atypical parkinsonism like progressive supranuclear palsy (PSP) or multiple system atrophy (MSA). Those conditions don’t respond to DBS. In fact, less than 10% of those patients see any benefit.

Second, you must have a clear, strong response to levodopa. If your tremors or slowness improve by more than 30% after taking your usual dose, you’re likely a good fit. If your symptoms barely budged, DBS won’t help much either.

Third, you need to have had Parkinson’s for at least five years. Why? Because early on, meds work fine. DBS is meant for when those meds start failing - not as a first-line treatment. Though new trials like EARLYSTIM-2 are now testing DBS in patients with just 3 years of disease, it’s still not standard.

Fourth, your thinking and mood must be stable. A score above 24 on the MMSE or 21 on the MoCA is the usual cutoff. If you have dementia, severe depression, or uncontrolled anxiety, DBS can make things worse. A full neuropsychological exam - usually 4 to 6 hours - is required before surgery.

Fifth, you need to be physically healthy enough for brain surgery. No major heart or lung disease. No uncontrolled diabetes. No history of strokes or brain bleeds. And you need to be willing to commit to months of follow-up visits for programming adjustments.

An awake patient during DBS surgery, with stylized brain circuits being calmed by electrical pulses, in a retro operating room setting.

What Happens During the Process?

The journey to DBS takes 3 to 6 months. It starts with a movement disorder specialist confirming your diagnosis and levodopa response. Then comes the neuropsych test, a high-resolution 3T MRI to map your brain, and a meeting with a neurosurgeon and a DBS coordinator.

The surgery itself is done while you’re awake - not because it’s painful, but because the team needs you to move, talk, and respond so they can find the exact spot to place the electrode. A frame is attached to your head, and tiny wires record brain signals as the surgeon drills through the skull. The whole thing takes 3 to 6 hours. Most people go home the next day.

But the surgery is just the beginning. The device doesn’t turn on right away. It takes 4 to 6 weeks for swelling to go down. Then, the real work starts: programming. This isn’t like adjusting a hearing aid. It’s a slow, trial-and-error process that can take 6 to 12 months. You’ll need to keep a symptom diary, note when you take meds, and show up every few weeks. Some centers have dedicated DBS coordinators who help with this. Others? You’re on your own.

What Are the Real Risks?

DBS is safe - but it’s not risk-free. About 1-3% of patients have a brain bleed during surgery. That’s rare, but serious. About 5-15% will have hardware problems: an infection under the skin, a wire that breaks or moves, or a battery that fails early. Revisions are common - about 1 in 10 people need another surgery within 5 years.

Then there are the subtle changes. Some people get worse at finding words, planning tasks, or remembering names. One Reddit user said, “My tremors are gone, but I struggle with executive function - planning meals takes 3x longer than before.” That’s not rare. And it’s not always reversible.

And then there’s the cost. In the U.S., DBS can run $50,000 to $100,000. Medicare covers it - but private insurers often drag their feet, requiring months of documentation proving you’ve tried and failed all other options. Even after approval, follow-up visits, battery replacements, and programming sessions add up.

What About the Alternatives?

There are other options. Focused ultrasound (like Exablate Neuro) can treat tremor without surgery. But it only works on one side of the brain and doesn’t help stiffness or slowness. It’s also not approved for widespread use in Parkinson’s - just tremor-dominant cases.

Lesioning procedures (like pallidotomy) destroy a small part of the brain to stop symptoms. They’re permanent. And once you do it, you can’t undo it. DBS is reversible. If it doesn’t help, you can turn it off. If your needs change, you can reprogram it.

For most people with advanced Parkinson’s and clear levodopa response, DBS still wins. But it’s not a magic bullet. It doesn’t stop the disease. It doesn’t fix balance problems or speech issues. It doesn’t cure depression. It only helps the motor symptoms that respond to levodopa.

Parkinson’s patients enjoying daily activities like driving and cooking, supported by DBS technology, in a bright, mid-century inspired community space.

Why So Few People Get It

Here’s the sad part: only 1-5% of people who meet the criteria for DBS actually get it. Why? Because most neurologists don’t refer patients early enough - or at all. The Parkinson’s Foundation says DBS is markedly underutilized. Many patients are never even screened. Others are told, “It’s too risky,” or “You’re too old.” But age isn’t the issue - health and response are.

And some patients have unrealistic expectations. One forum post read: “I thought DBS would stop disease progression - it doesn’t.” That’s a common misunderstanding. DBS treats symptoms. It doesn’t slow the underlying brain damage. If you’re hoping for a cure, you’ll be disappointed.

What to Expect After Surgery

Most people who qualify and stick with the process see dramatic improvements. In the EARLYSTIM trial, patients who got DBS early had a 23-point improvement in quality of life scores - twice as much as those who kept only medication. Many go from being housebound to driving, cooking, or playing with grandkids again.

But it’s not instant. It takes time. You’ll need patience. You’ll need to track your symptoms. You’ll need to show up for appointments. And you’ll need to accept that some changes - like a little trouble with word-finding - might stick around.

The key is choosing the right center. High-volume centers - those doing over 50 DBS procedures a year - have 20% fewer complications. If your hospital does fewer than 10 a year, ask if they refer patients to a larger program. Don’t settle for less.

The Future of DBS

The field is moving fast. Researchers are now looking at using genetic markers - like LRRK2 mutations - to predict who will respond best. Some are testing DBS for non-motor symptoms like depression and apathy. Others are linking DBS devices to smartwatches that track tremors and automatically adjust stimulation.

One day, DBS might be offered even earlier - maybe after just 3 years of Parkinson’s. But for now, the rule is simple: if your motor symptoms respond to levodopa, you’re still active, your mind is clear, and you’re ready to commit to the long haul - then DBS could be the best thing you’ve ever done for your quality of life.

Is DBS a cure for Parkinson’s disease?

No, DBS is not a cure. It doesn’t stop Parkinson’s from progressing. It only helps manage motor symptoms - like tremors, stiffness, and slowness - that respond to levodopa. It won’t fix balance problems, speech issues, or cognitive decline caused by the disease itself.

How long does the DBS battery last?

Non-rechargeable batteries last about 3 to 5 years and require replacement surgery. Rechargeable systems, like those in Medtronic’s Percept™ PC or Boston Scientific’s Vercise™ Genus™, last 9 to 15 years. But even rechargeable ones need regular charging - usually every few days - and can still need replacement if the device fails.

Can DBS help with speech or balance problems?

Not reliably. While DBS improves tremors, rigidity, and slowness, it only helps balance and gait issues in about 20-30% of patients. Speech problems can even get worse after DBS, especially with STN targeting. If speech or falling are your main concerns, DBS may not be the best choice - or you may need to combine it with physical therapy and speech training.

What if I have depression or anxiety? Can I still get DBS?

It depends. Severe, untreated depression or anxiety can make DBS outcomes worse. Most centers require these conditions to be stable before surgery. Some patients even get better after DBS - especially if their mood was tied to motor fluctuations. But if you have active major depression, you’ll likely need to be treated first with therapy or medication before being considered.

How do I know if my doctor is referring me too late?

If you’ve had Parkinson’s for more than 5 years and are struggling with OFF periods lasting more than 2 hours a day, or if you’re experiencing disabling dyskinesias despite taking meds, you’re likely a candidate. If your doctor hasn’t mentioned DBS by now, ask. Many patients are referred only after years of declining quality of life - and by then, it’s harder to regain function. Don’t wait until you’re housebound.

Tags: Parkinson's DBS deep brain stimulation DBS candidate selection DBS for Parkinson's DBS targets STN GPi
  • February 26, 2026
  • Vincent Kingsworth
  • 14 Comments
  • Permalink

RESPONSES

Brandie Bradshaw
  • Brandie Bradshaw
  • February 26, 2026 AT 13:13

DBS doesn't cure Parkinson's, but it restores agency. That's the real value. When you're trapped in OFF periods, your autonomy evaporates. You become a spectator in your own life. DBS doesn't promise perfection-it promises choice. The ability to stand up, walk to the kitchen, and make coffee without waiting for a pill to kick in. That's not medical progress. That's human dignity.

And yes, the side effects are real. Word-finding issues, mood shifts. But we treat those as trade-offs, not dealbreakers. You don't refuse a wheelchair because it makes your arms weaker. You use it because it lets you move again. This is the same.

The real tragedy isn't the surgery. It's that so many never even hear about this option until they're bedridden. Neurologists act like DBS is a last resort. It should be a mid-stage intervention. Early referral isn't risky-it's compassionate.

And let's stop pretending age is a barrier. My grandmother got DBS at 78. She started gardening again. She didn't need to be 50. She needed to be functional. That's the metric.

Vikas Meshram
  • Vikas Meshram
  • February 27, 2026 AT 13:39

There is a fundamental misconception in this article regarding GPi vs STN targeting. The VA/NINDS CSP #468 trial did not conclude GPi was superior for cognitive safety. It showed no significant difference in cognitive outcomes between the two targets at 36 months. The claim that GPi is 'safer' for cognition is misleading. In fact, STN allows greater levodopa reduction, which reduces dyskinesia-related neurotoxicity. The real advantage of GPi is in patients with pre-existing dyskinesias, not cognitive decline. This article oversimplifies a nuanced clinical decision.

Also, the 27% improvement from closed-loop DBS is from a small pilot cohort. The INTREPID trial is not yet peer-reviewed in its final analysis. We must avoid overhyping unreplicated data. Evidence-based medicine requires replication, not press releases.

Ben Estella
  • Ben Estella
  • February 28, 2026 AT 02:18

Look, I'm a vet. I've seen too many people get sold a dream. DBS isn't magic. It's a machine in your skull. And yeah, it works. But don't let them tell you it's a miracle cure. You're still gonna have Parkinson's. It just won't be screaming in your face all day.

And the cost? In this country, if you don't have good insurance, you're screwed. I know a guy who waited two years just to get approved. Two years. His wife had to quit her job to take care of him. That's not healthcare. That's a lottery.

Also, if you're thinking about this, don't go to some small clinic. Go to a center that does 50+ a year. If they can't show you their success rates, walk out. This isn't a haircut. It's brain surgery. You don't get a second chance.

Jimmy Quilty
  • Jimmy Quilty
  • March 1, 2026 AT 02:12

Let’s be real. Who really funds these DBS trials? Medtronic? Boston Scientific? The same companies that pushed opioids? The same ones that buried data on battery failures? The FDA approves devices based on short-term data. Long-term? They don’t care. The 'closed-loop' systems? They’re collecting your brainwave data. Who owns it? Who’s monitoring it? Are they selling it? Are they using it to predict your mood before you even feel it?

And don’t tell me about 'improvements.' I’ve read the FDA reports. 1 in 10 need revision surgery within 5 years. That’s not reliability. That’s a warranty nightmare. And the fact that they’re now linking DBS to smartwatches? That’s not innovation. That’s surveillance. They’re turning your neural activity into a data stream. Welcome to the future. It’s not what you think.

Sneha Mahapatra
  • Sneha Mahapatra
  • March 2, 2026 AT 08:55

I have a friend with Parkinson’s who got DBS. She didn’t talk about it much. But the change was quiet, deep, and beautiful. She started reading poetry again. She hadn’t done that in years. Not because the tremors were gone-but because the mental exhaustion of managing them was. The constant calculation: 'Will I make it to the bathroom? Will I spill my tea? Will I cry because I can’t hold the spoon?'

DBS didn’t fix her brain. It gave her space. Space to be human again. To be tired, not terrified. To be still, not stuck.

It’s not about the numbers. It’s about the moments. The quiet ones. The ones no trial can measure.

bill cook
  • bill cook
  • March 2, 2026 AT 16:27

I just want to say… I’m so sorry to everyone going through this. I lost my dad to Parkinson’s. He never got DBS. He said he didn’t want to be ‘a robot with wires.’ But I know now-he was scared. Scared of the surgery. Scared of losing himself. Scared they’d take away his voice. He didn’t know how much he could’ve gotten back.

I wish someone had told him it wasn’t about becoming something new. It was about remembering who he was.

Angel Wolfe
  • Angel Wolfe
  • March 3, 2026 AT 17:01

They say DBS helps motor symptoms but ignore the real cost. Who benefits? Big Pharma. Who pays? You. The battery replacement? $20K. The follow-ups? $10K a year. The fact that Medicare covers it? That’s just because they’re too lazy to deny it. But private insurers? They fight you tooth and nail. Why? Because they know this is the one thing that actually works. And they don’t want you to have it.

And let’s not forget-this tech was developed with DARPA funding. Your brain signals are being logged. Who has access? The VA? The DoD? Insurance companies? You think they don’t use this data to flag you as a 'high-risk patient'? They’re building neural profiles. This isn’t medicine. It’s social control.

Sophia Rafiq
  • Sophia Rafiq
  • March 5, 2026 AT 16:56

Been there. Got the scar. DBS was the best decision I ever made. I’m not saying it’s perfect. My speech got a little wonky. I forget words sometimes. But I can hold my granddaughter now. I can drive. I can cook without dropping the pan.

And yeah, the programming takes forever. I went to 17 appointments. But the coordinator? She was a lifesaver. She didn’t just tweak numbers. She asked how I felt. She listened. That’s what matters more than the tech.

If you’re on the fence? Do it. Not because it’s a cure. But because it’s a chance. To live. Again.

Ajay Krishna
  • Ajay Krishna
  • March 6, 2026 AT 08:22

Thank you for writing this with such clarity. I’ve seen too many patients dismissed because they’re 'too old' or 'too complex.' But Parkinson’s doesn’t care about age. It only cares about function. And if someone can still walk, talk, and respond to levodopa-they deserve the chance.

I tell my patients: DBS isn’t about fixing the brain. It’s about giving your brain a break. Letting it rest. Sometimes, that’s all it needs.

And yes, it’s not perfect. But neither is life. We don’t reject life because it’s imperfect. We learn to live within it. DBS helps you do that.

Charity Hanson
  • Charity Hanson
  • March 7, 2026 AT 23:58

I just want to say-you’re not alone. I’m from Nigeria, and I don’t have access to DBS. But I follow every study. I cry when I read about people who got it. Because I know what it’s like to watch someone you love shrink into silence.

Don’t let anyone tell you it’s too expensive or too risky. If you can get it-take it. Fight for it. Call your senator. Write to your insurer. Share your story. Because someone out there is waiting to hear that it’s possible.

You’re not just fighting for yourself. You’re fighting for everyone who won’t get the chance.

Noah Cline
  • Noah Cline
  • March 8, 2026 AT 11:09

Let’s cut through the noise. The data is clear: STN reduces levodopa dose more effectively than GPi. That’s a measurable, reproducible outcome. GPi’s advantage in dyskinesia reduction is marginal and context-dependent. The article misrepresents this as a categorical superiority. That’s dangerous. Clinicians need precision, not feel-good generalizations.

Also, the claim that 'many experts recommend GPi for older patients' is unsupported by the 2022 MDS guidelines. Those guidelines state target selection should be individualized based on symptom profile, not age. This article is misleading patients and clinicians alike.

Lisa Fremder
  • Lisa Fremder
  • March 9, 2026 AT 04:38

They say 'it’s not a cure' like that’s a bad thing. Like we should be grateful for a partial fix. But what about the people who get worse? The ones who lose their speech? Their memory? Their joy? They don’t get to write blog posts. They just disappear.

And don’t tell me about 'high-volume centers.' What about people in rural areas? In the South? In the Midwest? You think they can fly to Mayo Clinic every month? No. They’re stuck. And the system doesn’t care.

This isn’t medicine. It’s a privilege.

Justin Ransburg
  • Justin Ransburg
  • March 9, 2026 AT 17:11

Thank you for this comprehensive and compassionate overview. It’s rare to see a medical article that doesn’t reduce human experience to statistics. The emotional weight of regaining autonomy-of being able to hold your partner’s hand without shaking-is something no trial can quantify.

I’m a neurologist, and I’ve referred over 60 patients for DBS. Every one of them told me the same thing: 'I didn’t know I was still capable of joy.' That’s the real outcome. Not the 23-point QoL score. The joy.

Please, if you’re reading this and you’re considering DBS-don’t wait. Talk to your team. Ask for the neuropsych eval. Fight for the referral. You deserve to live, not just survive.

Sumit Mohan Saxena
  • Sumit Mohan Saxena
  • March 11, 2026 AT 14:07

As a clinician with over two decades of experience in movement disorders, I must emphasize that the criteria for DBS candidacy are not arbitrary. The five-point framework presented here is evidence-based and aligns with the 2021 International Parkinson and Movement Disorder Society guidelines. Deviation from these criteria results in suboptimal outcomes and increased risk of adverse events.

Notably, the requirement for a >30% levodopa response is not a preference-it is a predictor of DBS efficacy with a sensitivity of 89% and specificity of 93%. Patients who do not meet this threshold demonstrate no significant motor improvement post-DBS.

Furthermore, the notion that DBS should be offered earlier than 5 years is still investigational. The EARLYSTIM-2 trial remains ongoing. Premature implementation risks irreversible neurological compromise.

Patients must be thoroughly counseled on the longitudinal commitment: 12–24 months of programming, battery replacements, and neuropsychological monitoring. This is not a procedure. It is a lifelong partnership with a medical device.

Write a comment

Categories

  • Medications (78)
  • Health and Wellness (45)
  • Health and Medicine (36)
  • Pharmacy and Healthcare (19)
  • Mental Health (5)
  • Women's Health (4)
  • Industry (4)
  • Neurology (3)
  • Health Insurance (3)
  • Parenting (2)

ARCHIVE

  • March 2026 (6)
  • February 2026 (12)
  • January 2026 (29)
  • December 2025 (27)
  • November 2025 (18)
  • October 2025 (30)
  • September 2025 (13)
  • August 2025 (8)
  • July 2025 (6)
  • June 2025 (1)
  • May 2025 (4)
  • April 2025 (3)

Menu

  • About HealthExpress
  • HealthExpress Terms of Service
  • Privacy Policy
  • GDPR Compliance Framework
  • Contact Us

© 2026. All rights reserved.